Amobarbital and Cardiopulmonary Bypass
The Effect of Amobarbital on Myocardial Protection and Prognosis in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
Tongji Hospital
80 participants
Feb 1, 2025
INTERVENTIONAL
Conditions
Summary
Explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.
Eligibility
Inclusion Criteria4
- Age range: 18-65 years old, undergo elective cardiac surgery with extracorporeal circulation.
- ASA II-III;
- surgical duration is 3-6 hours;
- Sign the informed consent form
Exclusion Criteria8
- BMI less than 18 kg/m2 or greater than 30 kg/m2;
- Individuals with a history or potential history of drug abuse or alcohol dependence;
- Preoperative use of sedatives or analgesics;
- Individuals with severe liver and kidney dysfunction;
- Individuals who are allergic or potentially allergic to barbiturates;
- Patients with coagulation dysfunction, endocrine disorders, or other conditions that affect hemodynamic status;
- Participated in other clinical studies in the past 3 months;
- The researchers believe that participants who are not suitable to participate in this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Amobarbital 1mg/kg is given prior to cardiopulmonary bypass
midazolam 0.1mg/kg is given prior to cardiopulmonary bypass
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06757868